Bendamustine-bortezomib-dexamethasone in heavily pretreated immunotherapy-refractory myeloma

BVD in heavily pretreated multiple myelomaПодробнее

The role of pomalidomide-dexamethasone in patients with multiple myelomaПодробнее

Dan T. Vogl, MD: Selinexor Plus Low-Dose Dexamethasone in “Penta-Refractory” Myeloma PatientsПодробнее

Breakthrough in relapsed multiple myeloma with PANORAMA 1 studyПодробнее

Bendamustine-bortezomib-dexamethasone in R/R multiple myelomaПодробнее

DCEP and bendamustine/prednisone as salvage for refractory MMПодробнее

Peter Voorhees, MD: Approach to Relapsed/Refractory Multiple Myeloma: MCRT Charlotte 2018Подробнее

The Future of Antibody Therapies and Drug Conjugates in Multiple MyelomaПодробнее

Impact of recent bendamustine treatment on outcomes after CAR-T therapy in patents with LBCLПодробнее

Selinexor for multiple myelomaПодробнее

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее

GEM-SELIBORDARA: selinexor plus daratumumab, bortezomib, and dexamethasone in R/R multiple myelomaПодробнее

ICAHO19 - Multiple Myeloma session: relapsed/refractory myelomaПодробнее

The safety and efficacy of isatuximab, bortezomib, lenalidomide, and dexamethasone in NDMMПодробнее

The importance of reporting real world data in myelomaПодробнее

The importance of real-world data in multiple myelomaПодробнее

Bendamustine with dexamethasone in R/R systemic AL amyloidosisПодробнее

The importance of treating high-risk smoldering myelomaПодробнее

When Myeloma Comes BackПодробнее